DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY

ONC201 is the first bitopic antagonist of dopamine receptor D2 (DRD2) in oncology clinical trials, which have shown that the small molecule is well tolerated and induces durable tumor regressions in H3 K27M-mutant glioma patients. ONC201 possesses a unique tri-heterocyclic core structure that prompt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Prabhu, Varun, Cuoco, Caroline, Jung, Jinkyu, Rahman Kawakibi, Abed, Willette, Blair, Day, Marilyn, Anantharaman, Lakshmi, Charter, Neil, Rucker, Joseph, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Gilbert, Mark, Benjamin Free, R, Sibley, David, Allen, Joshua
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Drug Discovery
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846870/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.271
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados